Jianli Qiu

Jianli Qiu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2025 in Biology Direct
Verified
Journal Article
Open access
PDF file
JQJianli Qiu
Jianli Qiu
YQYitong Qu
Yitong Qu
YLYinli Li
Yinli Li
CLCancan Li
Cancan Li
JWJunling Wang
Junling Wang
CYChai Yu-Na
Chai Yu-Na
The Rho GTPase Rac family small GTPase 1 (RAC1) is considered a promising fibrotic therapeutic target, but the role of its activator, dedicator of cytokinesis 2 (DOCK2), in liver fibrosis is largely unknown. This study aimed to investigate the expression and role of DOCK2 in cholestasis-induced liver fibrosis and to further explore the potential mechanisms. Cholestasis was induced in male C57BL/6 mice by bile duct ligation (BDL). DOCK2 knockdown was achieved by tail vein injection of adenovirus containing DOCK2-targeting shRNA. The effect of DOCK2 knockdown on cholestatic liver injury was evaluated at different time points after BDL. Hepatic DOCK2 expression gradually increased after BDL. Knockdown of DOCK2 reduced the necrotic area in BDL liver and downregulated serum levels of liver injury indicators. At 3d post-BDL (acute phase), DOCK2 knockdown alleviated M1 macrophage inflammation in the liver, as evidenced by reduced infiltrating iNOS + macrophages and inflammatory cytokines and mitigated NLRP3 inflammasome activation. At 14d post-BDL (chronic phase), DOCK2 knockdown suppressed hepatic stellate cell (HSC) activation and liver fibrosis as indicated by decreased α-SMA + HSCs and extracellular matrix deposition. In vitro experiments further demonstrated that DOCK2 knockdown suppressed M1 macrophage polarisation and HSC to myofibroblast transition, accompanied by inhibition of RAC1 activation. In summary, this study demonstrates for the first time that the RAC1 activator DOCK2 regulates M1 macrophage polarisation and hepatic stellate cell activation to promote cholestasis-induced liver inflammation and fibrosis, suggesting that DOCK2 may be a potential therapeutic target in cholestatic liver injury.

13 April 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XCXinxin Cui
Xinxin Cui
JQJianli Qiu
Jianli Qiu
YXYan Xu
Yan Xu
ZGZhiwei Guan
Zhiwei Guan
YDYing Ding
Ying Ding
XRXianqing Ren
Xianqing Ren
Necrotizing enterocolitis (NEC) is one of the most severe intestinal diseases affecting preterm infants, characterized by high mortality rates and significant long-term complications, which present substantial challenges to clinical management. The primary pathological mechanism underlying NEC is the immature development of the intestinal barrier in preterm infants, which fails to adequately resist luminal pathogen invasion, triggering uncontrolled inflammatory responses and tissue damage. Additionally, intestinal dysbiosis further compromises the integrity of the intestinal barrier. In recent years, growing attention has been given to the role of tryptophan metabolites in maintaining intestinal barrier integrity. As an essential amino acid, tryptophan metabolites—particularly those derived from gut microbiota, such as indole compounds—have been shown to exert significant barrier-protective effects through multiple mechanisms, including the activation of the aryl hydrocarbon receptor (AhR), upregulation of tight junction protein expression, inhibition of inflammatory responses, and promotion of epithelial cell repair. This review aims to summarize the major biological pathways of tryptophan metabolism, with particular emphasis on the molecular mechanisms by which microbial indole derivatives enhance the physical, chemical, and immune barriers. By synthesizing both preclinical studies and clinical evidence, this article explores the translational potential of tryptophan metabolite-targeted strategies for NEC prevention, providing a theoretical foundation for the development of precise preventive interventions.

26 December 2022 in World Journal of Clinical Cases
Verified
Journal Article
Open access
LYLu-Lu Yang
Lu-Lu Yang
YXYan Xu
Yan Xu
JQJianli Qiu
Jianli Qiu
QZQian-Yi Zhao
Qian-Yi Zhao
MLMan-Man Li
Man-Man Li
HSHui Shi
Hui Shi
Congenital nephrogenic diabetes insipidus (CNDI) is a rare hereditary disorder. It is associated with mutations in the arginine vasopressin receptor 2 (AVPR2) gene and aquaporin 2 (AQP2) gene, and approximately 270 different mutation sites have been reported for AVPR2. Therefore, new mutations and new manifestations are crucial to complement the clinical deficiencies in the diagnosis of this disease. We report a case of a novel AVPR2 gene mutation locus and a new clinical mani-festation. We describe the case of a 48-d-old boy who presented with recurrent fever and diarrhea 5 d after birth. Laboratory tests showed electrolyte disturbances and low urine specific gravity, and imaging tests showed no abnormalities. Genetic testing revealed a novel X-linked recessive missense mutation, c.283 (exon 2) C>T (p.P95S). This mutation results in the substitution of a proline residue with a serine residue in the AVPR2 protein sequence. The diagnosis of CNDI was confirmed based on the AVPR2 gene mutation. The treatment strategy for this patient was divided into two stages, including physical cooling supplemented with appropriate amounts of water in the early stage and oral hydrochlorothia-zide (1-2 mg/kg) after a clear diagnosis. After follow-up of one and a half years, the patient gradually improved. AVPR2 gene mutations in new loci and new clinical symptoms help clinicians understand this disease and shorten the diagnosis cycle.

10 September 2026 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
HCHang Chen
Hang Chen
YXYan Xu
Yan Xu
ZGZhiwei Guan
Zhiwei Guan
JQJianli Qiu
Jianli Qiu
XXXinyu Xu
Xinyu Xu
XRXianqing Ren
Xianqing Ren
Bacterial pneumonia remains a major cause of infectious mortality, and antimicrobial resistance has intensified interest in host-directed therapy (HDT). Recent bronchoalveolar lavage fluid (BALF) and peripheral blood atlases (2024–2025) provide single-cell evidence from human disease, but the main translational gap is prioritization rather than catalog expansion. In this review, we reorganize published datasets from bacterial pneumonia and related lung infection cohorts (>500,000 cells; 2020–2026) into a state-prioritization scheme termed “treatable cell states.” Evidence is currently strongest for severity-linked expansion of indoleamine 2,3-dioxygenase 1–positive/programmed death-ligand 1–positive (IDO1+/PD-L1+) macrophages and pathological neutrophils; exhausted-like CD8+ T-cell states show emerging human transcriptomic and translational support but still require protein-level, functional, and longitudinal validation, whereas evidence for injured epithelium and repair-failed stromal states in bacterial pneumonia remains partly inferential and draws on adjacent lung-injury literature. We therefore treat the six proposed state categories as a ranked hypothesis set for macrophage-, neutrophil-, T-cell-, epithelial-, and stromal-directed interventions, not as validated clinical targets. Most proposed interventions still require longitudinal and functional validation before routine bedside use.